Table 1.
Baseline Clinical Characteristics and Laboratory Data
| Control Group (n=31) | EPA Group (n=31) | EPA+DHA Group (n=35) | P Value | |
|---|---|---|---|---|
| Age, y | 63 (55–73) | 66 (57–70) | 67 (59–70) | 0.862 |
| Male sex | 27 (87) | 24 (77) | 28 (81) | 0.596 |
| Hypertension | 22 (71) | 18 (58) | 16 (46) | 0.117 |
| Diabetes mellitus | 11 (35) | 3 (10)* | 11 (31) | 0.043 |
| Current smoking | 16 (52) | 13 (42) | 13 (37) | 0.488 |
| Body mass index, kg/m2 | 24.7 (22.5–25.7) | 24.3 (23.3–26.7) | 25.0 (23.1–26.9) | 0.533 |
| Clinical presentation | 0.168 | |||
| STEMI | 22 (71) | 25 (81) | 29 (83) | |
| NSTACS | 9 (29) | 6 (20) | 6 (17) | |
| Target vessel | 0.860 | |||
| LAD | 15 (48) | 11 (36) | 2 (34) | |
| LCX | 7 (23) | 7 (23) | 10 (29) | |
| RCA | 9 (29) | 13 (42) | 13 (37) | |
| Location of target plaque | 0.243 | |||
| Culprit vessel | 10 (32) | 14 (45) | 9 (26) | |
| Nonculprit vessel | 21 (68) | 17 (55) | 26 (74) | |
| Laboratory data | ||||
| FBS, mg/dL | 113 (92–167) | 122 (107–143) | 124 (103–168) | 0.526 |
| HbA1c, % | 5.9 (5.6–7.1) | 5.9 (5.6–6.0) | 6.0 (5.7–6.5) | 0.585 |
| SCr, mg/dL | 0.9 (0.7–1.0) | 0.8 (0.7–0.9) | 0.8 (0.78–1.0) | 0.536 |
| Triglycerides, mg/dL | 106 (73–141) | 117 (91–135) | 96 (67–131) | 0.316 |
| Total cholesterol, mg/dL | 183 (166–215) | 195 (162–217) | 182 (163–207) | 0.851 |
| LDL‐C, mg/dL | 125 (105–140) | 120 (99–142) | 118 (99–145) | 0.953 |
| HDL‐C, mg/dL | 43 (36–48) | 45 (38–51) | 46 (38–54) | 0.600 |
| EPA, mg/dL | 43.0 (29.2–62.5) | 37.0 (23.5–66.1) | 45.2 (32.9–66.3) | 0.848 |
| AA, mg/dL | 165.1±41.7 | 163.4±36.3 | 163.1±46.5 | 0.980 |
| DHA, mg/dL | 112.8±32.8 | 112.5±36.7 | 113.1±29.9 | 0.997 |
| EPA/AA ratio | 0.31 (0.20–0.43) | 0.26 (0.15–0.43) | 0.33 (0.18–0.40) | 0.739 |
Values are presented as mean±SD, median (interquartile interval), or n (percentage). AA indicates arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LAD, left anterior descending artery; LCx, left circumflex artery; LDL‐C, low‐density lipoprotein cholesterol; NSTACS, non–ST‐elevation acute coronary syndrome; RCA, right coronary artery; RCA, right coronary artery; SCr, serum creatinine; and STEMI, ST‐segment–elevation myocardial infarction.
*
P<0.05 vs control group.